SAN FRANCISCO (GenomeWeb) – Veracyte CEO Bonnie Anderson said this week that the company is working on two new products in the realm of thyroid and lung cancer diagnostics that would expand on the existing Afirma and Percepta tests it currently markets in those areas.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.